An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Overview of attention for article published in New England Journal of Medicine, June 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 130 news outlets
blogs: 16 blogs
policy: 2 policy sources
twitter: 554 X users
patent: 36 patents
facebook: 16 Facebook pages

wikipedia: 9 Wikipedia pages
reddit: 9 Redditors
f1000: 1 research highlight platform
guideline: 6 clinical guideline sources
bluesky: 1 Bluesky user

Readers on

mendeley: 1040 Mendeley

So far, Altmetric has seen 8 Guidelines that reference this research output.

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

Clinical guideline published by National Institute for Health and Care Excellence (NICE) on 09 Jul 2026

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

UK best practice recommendations for children and young people <18 years with pre‐stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED)

Clinical guideline published by British Society for Paediatric Endocrinology and Diabetes (BSPED) on 23 Sep 2025

The BSPED aims to improve the care of children and young people with endocrine disorders and diabetes mellitus

Glycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice Guideline

Clinical guideline published by Diabetes Canada on 01 Feb 2025

Diabetes Canada's mission is to prevent diabetes and its complications; help people with diabetes live healthy lives; and work to find a cure.

Screening and care for preclinical stage 1–2 type 1 diabetes in first-degree relatives: French expert position statement

Clinical guideline published by Société Francophone du Diabète (SFD) on 13 Dec 2024

The Société Francophone du Diabète (SFD) is a professional organization dedicated to advancing diabetes research and improving care for diabetes and metabolic diseases. Comprising researchers and health professionals, it promotes guidelines, organizes events, and supports educational initiatives in the francophone community.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity, including 4 additional posts.